SHELTON, CONNECTICUT -- Thursday, December, 1, 2016 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), announced today that it has published a letter from the Company's CEO addressing its shareholders on its website (www.nanoviricides.com).
In this letter, Dr. Eugene Seymour, CEO of the Company, surveys the Company's accomplishments in the past fiscal year that ended June 2016, and more recent events. The letter describes the progress that the Company has made towards entering human clinical trials. The Company believes that a nanoviricide® skin cream against shingles will be its first drug to go into human clinical studies. The Company expects that additional HerpeCiode™ program topical drug candidates will follow the shingles drug candidate into the clinic.
In addition, the letter lays out the steps that the Company will be accomplishing in the near future as it advances the shingles drug into human trials. Over one million cases of shingles are seen in the US annually with 70% of these cases being found in elderly and immunocompromised individuals.
The Company has four different drugs in development in the HerpeCide program. All of these high priority drugs are topical treatments, which is expected to enable a relatively rapid regulatory process as compared to systemic drugs.
Further, the Company has four more systemically delivered drugs in different preclinical development stages that are expected to mature towards the clinic. The Company continues to work on these drug candidates at lower priorities, due to resource limitations.
The Company believes its future is very bright, with four topical drug candidates and additional four systemic drug candidates in development. These drugs taken together address over $40Bn in market size in herpesviral diseases (cold sores, genital ulcers, herpes keratitis, shingles, and others), influenzas (broad spectrum injectable drug for hospitalized patients with severe viral influenzas, oral nanomedicine drug for out-patients with influenza), HIV, and dengue viruses.
The Company believes it now has the infrastructure to develop antiviral drugs from discovery all the way to clinical product manufacture in its new campus in Shelton, CT. This has strengthened the Company's position as it would allow the Company to become a stand-alone antiviral pharmaceuticals company. The Company believes it will pursue out-licensing or co-development strategies with other partners where possible.
The letter is available at http://www.nanoviricides.com/2016-ceo-letter.pdf.
About NanoViricidesFDA refers to US Food and Drug Administration. EMA refers to the European Union’s office of European Medical Agency.